Immunome, Inc. (IMNM)
NASDAQ · Manufacturing · Pharmaceutical preparations
IMNM price, last 12 months
Key stats
- Previous close
- $22.34
- Open
- $22.70
- Day range
- $21.15 – $22.86
- 52-week range
- $10.00 – $30.06
- Volume
- 2.3M
- Avg volume (20 days)
- 1.3M
- Market cap
- $2.4B
Performance
Technicals and fundamentals
About Immunome, Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $2.4B